In this issue:
High-dose oral thiamine for reducing fatigue in quiescent IBD
Withdrawing immunomodulators/biologics from IBD regimens
Vedolizumab treatment persistence and safety after 2 years
T3/T4 ratio for predicting outcomes to biologics in elderly IBD
Missed opportunities for CRC diagnosis in IBD patients
A Firmicutes spore-based microbiome therapeutic for mild-to-moderate UC
Relationship between histological and endoscopic endpoints, and ustekinumab efficacy in UC
Changes in early surgery requirements in IBD in the biologic era
Healthy lifestyle reduces mortality in IBD
SARS-COV-2 infection in IBD patients
Please login below to download this issue (PDF)